Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Eldecalcitol May Increase Bone Mineral Density in Poor Responders to Bisphosphonates

Key clinical point: Among patients with osteoporosis who have diminished long-term response to bisphosphonate therapy, the addition of eldecalcitol may reduce bone turnover markers and increase bone mineral density.

Major finding: Average low lumbar bone mineral density increase rate was 0.2% from 2 to 1 years before eldecalcitol administration, −0.7% during the year before eldecalcitol administration, and 2.9% during 1 year of eldecalcitol therapy.

Study details: A prospective cohort study of 42 postmenopausal Japanese women with primary osteoporosis who were poor responders to bisphosphonates.

Disclosures: The authors reported no relevant conflicts of interest.

Citation:

Kamimura M, et al. Osteoporos Sarcopenia. 2019 Jun 28. doi: 10.1016/j.afos.2019.06.001.